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ABSTRACT
Background
Although advances in rehydration therapy have made cholera a treatable disease with low
case-fatality in settings with appropriate medical care, cholera continues to impose
considerable mortality in the world’s most impoverished populations. Internationally licensed,
killed whole-cell based oral cholera vaccines (OCVs) have been available for over a decade, but
have not been used for the control of cholera. Recently, these vaccines were shown to confer
significant levels of herd protection, suggesting that the protective potential of these vaccines
has been underestimated and that these vaccines may be highly effective in cholera control
when deployed in mass immunization programs. We used a large-scale stochastic simulation
model to investigate the possibility of controlling endemic cholera with OCVs.
Methods and Findings
We construct a large-scale, stochastic cholera transmission model of Matlab, Bangladesh. We
find that cholera transmission could be controlled in endemic areas with 50% coverage with
OCVs. At this level of coverage, the model predicts that there would be an 89% (95%
confidence interval [CI] 72%–98%) reduction in cholera cases among the unvaccinated, and a
93% (95% CI 82%–99%) reduction overall in the entire population. Even a more modest
coverage of 30% would result in a 76% (95% CI 44%–95%) reduction in cholera incidence for
the population area covered. For populations that have less natural immunity than the
population of Matlab, 70% coverage would probably be necessary for cholera control, i.e., an
annual incidence rate of   1 case per 1,000 people in the population.
Conclusions
Endemic cholera could be reduced to an annual incidence rate of   1 case per 1,000 people
in endemic areas with biennial vaccination with OCVs if coverage could reach 50%–70%
depending on the level of prior immunity in the population. These vaccination efforts could be
targeted with careful use of ecological data.
The Editors’ Summary of this article follows the references.
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The global burden of cholera remains substantial. In 2005,
131,943 cases and 2,272 deaths were reported to the WHO,
and recently major, sustained epidemics have been reported
in West Africa [1]. These statistics are gross underestimates, as
many cholera-endemic countries do not report cholera to the
WHO, including Bangladesh, which has among the highest
rates of cholera in the world. More realistic estimates of the
global burden of cholera mortality place the ﬁgure at
100,000–150,000 deaths per year. This high burden occurs
because cholera targets the most impoverished populations,
which often lack access to centers that can appropriately
administer life-saving rehydration therapy.
This continuing high burden highlights the need for
interventions to prevent cholera. While improved water and
sanitation constitute the ultimate basis for the prevention of
cholera, this is a far-off goal for the impoverished settings in
which cholera thrives. Vaccines constitute near-term options
for cholera control. During the past 20 y, killed oral cholera
vaccines (OCVs) have been shown to be safe and protective in
populations with endemic cholera [2,3]. A large-scale com-
munity OCV vaccine trial in Vietnam showed that mass
vaccination for endemic cholera is operationally feasible in a
developing country setting [4]. Yet, because these vaccines
have moderate levels of protective efﬁcacy, they have not
been routinely adopted as control measures for endemic
cholera [5,6]. Recently, however, a reanalysis of a ﬁeld trial of
killed OCVs in Bangladesh demonstrated that these vaccines
are capable of inducing herd protection of nonvaccinees, as
well as enhanced protection of vaccinees, when even modest
levels of vaccine coverage of the targeted population are
attained [7]. These observations prompted us to re-examine
the potential impact of use of these vaccines in mass
immunization programs on the control of endemic cholera.
In this paper, we use a large-scale stochastic simulation model
to investigate potential control of endemic cholera with OCV.
Methods
In the mid-1980s, a randomized controlled vaccine trial
with OCV in Matlab, Bangladesh, yielded 70% direct vaccine
efﬁcacy for up to two years [2,3]. We use information about
Matlab, Bangladesh to construct a model of the population as
it was in 1985, consisting of 183,826 participants. These
individuals were mapped into families and families were
distributed in ‘‘baris,’’ i.e., patrilineally related household
clusters [7]. In the model, baris are further clustered into
subregions of about 6 km
2 that are considered to be the
geographic cholera transmission areas. The model (see
Figures S1–S5 and Texts S1 and S2) represents the number
of contacts that a typical person makes with sources of
potential cholera transmission in the course of a day. The age
and bari size distributions of the population are based on
data from Ali et al. [7]. Women and children are assumed to
come into contact with sources of infection in the subregion
where they live, while working males are assumed to make
contact with infective sources in the subregion where they
live as well as where they work. The population structure and
movement distance function are given in Text S1.
The modeled natural history of cholera is described in
Figure 1. The distributions of the duration of the incubation
and infectious periods and other important natural history
parameters are taken from the cholera literature [8–10]. The
model was calibrated to cholera illness incidence data from a
large cholera vaccine trial in the Matlab ﬁeld area of the
International Centre for Diarrhoeal Disease Research, Ban-
gladesh (ICDDR,B), that took place from 1985 to 1989 [2,3,11].
OCV or placebo (killed E. coli) was offered to children 2–15 y
of age and women over 15 y. Matlab has cholera transmission
year around, but it generally experiences a large cholera
epidemic from September through December and then a
somewhat smaller epidemic from March through May [12].
Although the deﬁnition of endemic cholera may vary, we
deﬁne this pattern of cholera transmission to be ‘‘endemic,’’
i.e., at least a low level of cholera all year round, with periodic
larger epidemics. For our analysis we assess cholera risk in
individuals residing in different subregions in the ﬁeld trial
area. Subregions are useful for cluster analysis because they
are geographically discrete with local sources of water.
Infected people within subregions can possibly transmit the
disease person-to-person [13]; more commonly transmission
occurs when feces enter local ponds where vibrios from the
feces are ampliﬁed in organic material, especially plankton,
during the epidemic periods [14]. We deﬁne an infection
function (see Text S2) that gives each susceptible person’s
daily probability of infection from all possible sources of
infection created by infected people excreting cholera vibrios
into the environment or through more direct contact. This
probability of infection is proportional to the number of
vaccinated and unvaccinated people in the subregion where
contact is speciﬁed to occur (see Text S2).
We base the indirect, overall, and total vaccine effective-
ness on the reduction in infection rates when comparing the
appropriate groups within a subregion with no vaccination to
a comparable subregion with a fraction f . 0o ft h e
population vaccinated (Figure 2). The direct effectiveness
compares the vaccinated to the unvaccinated within a
subregion (Figure 2). Since the vaccinated and unvaccinated
in a particular subregion are subject to the same intensity of
Figure 1. Basic Model Parameter Distributions
Modeled natural history of cholera [8–10]. People start out partially
susceptible. Newly infected people pass through the incubating state
(mean 3.6 d) and infectious state (mean 10.5 d) after which they recover
with partial immunity or die. The probability distributions of the
incubation and infectious periods are shown in the figure. We assume
that 10% of infected people develop overt cholera symptoms and 90%
will be asymptomatic. We further assume that symptomatic people are
ten times as infectious as asymptomatics. Additionally, this model allows
for 75% of symptomatic working males to withdraw to their subregion
[Pr(withdrawal after ill)].
doi:10.1371/journal.pmed.0040336.g001
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the vaccine coverage [15]. This condition held for the
randomized vaccine trial; however, if in actual practice
vaccinated people tend to have less risk of cholera infection
than unvaccinated people due to factors other than vacci-
nation itself, then the actual vaccine effectiveness measures
would be attenuated. In addition, we assume that the vaccine
induces immunity that results in a proportional reduction in
the probability of infection per contact with an infectious
source [15], i.e., a leaky vaccine. For our application, we
further average over all the subregions within vaccination
coverage strata.
Vaccines would need to contain antigens that are reactive
or have cross-reactivity to current circulating strains of
cholera in endemic areas [12]. These would include the Vibrio
cholerae O1 El Tor biotype with both the Ogawa and Inaba
serotypes, as well as the O139 serogroup that has been
circulating since 1993.
Since we are modeling endemic cholera, we assume that
there is signiﬁcant partial population-level immunity due to
past exposure to cholera. The actual level of such protection
is complex and difﬁcult to determine. Past analysis of cholera
incidence in Matlab reveals that there is partial waning of
population-level immunity over six months [12], although
there is reason to believe that there is some partial long-term
immunity as well [16,17]. Since we are modeling endemic
cholera over a limited (one year) time horizon, we assume
that infection in individuals results in complete immunity for
the remainder of the simulation period, but this immunity
would be partially lost with time. We also model populations
that may not have as high a level of partial population natural
immunity than that of Matlab. We do this by increasing the
relative susceptibility of the simulation population in con-
trast to Matlab. For example, people in a population
relatively new to cholera could have a susceptibility that is
twice as high as that of Matlab per contact with an infectious
source. In this case, the probability of infection per contact
with an infectious source would be twice has high as that
probability in Matlab. The relative susceptibility multiplier
would be two in this case (see Text S3).
Results
We calibrated the simulation model using cholera inci-
dence data observed in the ﬁrst year of the vaccine trial
(Table 1) over a 180 d period in order to capture all the
cholera transmission during the large annual cholera out-
break. This was done by varying the transmission probability,
p (see Figure S6 and Text S2), such that the differences
between the observed incidence rates and the simulated
incidence rates in Table 1 were minimized. The estimated
reproductive number was 5.0 with a standard deviation of 3.3
(see Text S2). A summary of the parameters and their baseline
values are shown in Table S1. The vaccine coverage levels in
the target population and the effective coverage in the entire
population from the trial are summarized in Table 1. We
assume that vaccinated people receive an effective regimen of
two doses. The observed cholera incidence rates among the
unvaccinated ranged from a high of 7.0 cases/1,000 over 180 d
for the subregions with the lowest coverage in the target
population, centered at 14%, to 1.5 cases/1,000 for the highest
coverage, centered at 58%. The observed cholera incidence
rates among the vaccinated ranged from a high of 2.7 cases/
1,000 for the subregions with the lowest coverage to 1.3 cases/
1,000 for the highest coverage. We set the vaccine efﬁcacy
(VE) for susceptibility to VES¼0.7 [2,3] and for infectiousness
to VEI ¼ 0.5. The simulated incidence rates provided a good
ﬁt to the data based on a v
2 goodness-of-ﬁt test for frequency
data (p ¼ 0.84, 9 degrees of freedom). Figure 3A–3D show the
number of cases over time comparing the unvaccinated to the
vaccinated populations. Videos S1 and S2 show the spatial–
temporal epidemics at different coverage levels. For effec-
tiveness measures, we compare the intervention subregions to
hypothetical subregions that receive no vaccine, i.e., f ¼ 0.
Table 2 shows the indirect, total, and overall effectiveness
estimated by the model for possible coverage levels when
comparing coverages in the entire population, 2 y of age and
older, ranging from 10% to 90% compared to no vaccination.
For example, the average indirect effectiveness, comparing a
population with a coverage of 30% to one with no
vaccination, is 70% (also see Figure S7). This indicates that
on average, the cholera incidence among unvaccinated
people in a population with 30% coverage would be reduced
by 70% compared with a completely unvaccinated popula-
tion. At this level of coverage, the total effectiveness of 90%
indicates high protection for a vaccinated person in a
population with 30% vaccination coverage, while the overall
effectiveness of 76% indicates a good overall reduction in
risk to the overall population. According to the model,
around 40 cases of cholera are prevented per 1,000-dose
Figure 2. Schematic of Effectiveness Comparisons for Two Subregions
Subregion 1 has a fraction f1 . 0 people vaccinated, while the
comparison subregion 2 has nobody vaccinated, i.e., f2 ¼ 0. We let rij be
the cholera infection rate for people in subregion j with vaccination
status i, where i ¼ 0 for unvaccinated and i ¼ 1 for vaccinated. The
indirect effect of vaccination is measured by comparing the infection
rates between the unvaccinated in the two subregions. Thus, the indirect
vaccine effectiveness, i.e., IVEF, when comparing subregion 1 to 2 is
IVEF12 ¼ 1   (r01/r02). The overall effect of vaccination is measured by
comparing the average (over the vaccinated and unvaccinated groups)
infection rates between the two subregions. Thus, the overall vaccine
effectiveness, i.e., OVEF, is OVEF12 ¼ 1   (r.1/r.2), where the   indicates
averaging over the vaccinated and unvaccinated. The total effect of
vaccination is measured by comparing the infection rate in the
vaccinated in subregion 1 to the unvaccinated in subregion 2. Thus,
the total vaccine effectiveness, i.e., TVEF, is TVEF12 ¼ 1   (r11/r02). The
direct effect of vaccination is measured by comparing the infection rates
in the vaccinated and unvaccinated in the same subregion. The direct
vaccine effectiveness, i.e., DVEF, is DVEF1¼1 (r11/r01). In general, these
effectiveness measures could be computed across any gradient of
coverage, jf1   f2j, other than those with f2 ¼ 0.
doi:10.1371/journal.pmed.0040336.g002
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Controlling Endemic Choleraregimens of vaccine at low coverage and 13 cases at high
coverage. At coverage levels of 50% and higher, all levels of
effectiveness exceed 85%, resulting in the nearly total
control, i.e., an overall annual cholera incidence of about 1
case per 1,000 people, of cholera transmission.
From Table 1, we see that the simulated direct effectiveness
at all coverage levels is estimated from the simulations to be
about 66%, while the vaccine efﬁcacy for susceptibility, VES is
pre-set at 70%. This small underestimation is due to the fact
that we model the vaccine effect to be a 70% reduction in the
risk of infection per contact with an infective source, i.e., a
leaky effect, but we use the risk ratio estimator of vaccine
effectiveness over the entire cholera epidemic. We do this for
the purpose of comparison, as this was the primary estimator
used in the cholera vaccine trial in Matlab [2]. We have shown
that an estimator based on the monthly hazard ratio gives a
similar, but more accurate estimate of actual vaccine efﬁcacy
[3]. Also note from Table 1 that the observed estimate of the
direct effectiveness is only 14% in the highest vaccination
coverage category when it should be around 66%. This
discrepancy probably reﬂects small sample bias due to the low
cholera incidence in the highest vaccine coverage category.
Figure 4 shows the overall effectiveness estimated by the
model for possible coverage levels in populations at different
levels of relative susceptibility compared to Matlab. For
populations that are 1.5 times as susceptible as those in
Matlab, 50% coverage would still be sufﬁcient to achieve an
overall effectiveness of 80%. However, for populations that
are 2–2.5 times as susceptible, 70% vaccine coverage would be
necessary to achieve control.
Since vaccine efﬁcacy can vary for different ﬁeld settings
and vaccines, a sensitivity analysis was carried out on the VES
and the VEI to determine the minimum efﬁcacy needed to
maintain control at the vaccine coverages explored above.
The VES and VEI were varied from 0.3 to 0.8 (Figures S8–S15).
These analyses reveal that theVES could be as low as 0.5 and
Table 1. Vaccination Coverage, Average Incidence Rates, and Direct Effectiveness (Calibration Runs)
Vaccination Coverage (%) Mean Cases/1,000 (95% CI) Mean Direct Effectiveness (%) (95% CI)
Target Population Overall Population Placebo Vaccinated Observed Simulated
Observed Simulated Observed Simulated
14 9 7.0 (6.5 to 7.5) 7.8 (1.9 to 14.8) 2.7 (1.9 to 3.5) 2.8 (0.5 to 6.1) 62 65 (52 to 77)
31 20 5.9 (5.4 to 6.4) 4.7 (0.9 to 10.2) 2.5 (2.0 to 3.0) 1.7 (0.3 to 3.8) 58 65 (55 to 76)
38 25 4.7 (4.2 to 5.2) 3.8 (0.8 to 8.6) 1.6 (1.2 to 2.0) 1.3 (0.2 to 3.4) 67 65 (54 to 77)
46 30 4.7 (4.2 to 5.2) 2.8 (0.5 to 6.8) 2.3 (1.9 to 2.7) 1.0 (0.1 to 2.5) 52 66 (54 to 79)
58 38 1.5 (1.2 to 1.8) 1.8 (0.3 to 4.8) 1.3 (1.0 to 1.6) 0.6 (0.1 to 1.8) 14 66 (51 to 80)
doi:10.1371/journal.pmed.0040336.t001
Figure 3. Simulated Number of Cholera Cases per 1,000 over a 180-Day Period in the Matlab Study Population for a Single Stochastic Realization
(A) No vaccination.
(B) 14% vaccination coverage of women and children.
(C) 38% vaccination coverage.
(D) 58% vaccination coverage.
doi:10.1371/journal.pmed.0040336.g003
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Controlling Endemic Cholerathe VEI as low as 0.3 to still maintain control of cholera, as
long as the vaccine coverage were 50% or higher. Further
sensitivity analysis on the vaccine coverage (Figures S13–S15)
reveals that vaccine coverage should be at least 50% to
maintain control.
Sensitivity analyses also were performed for values of the
seasonal boost factor, the relative infectiousness of sympto-
matic infectives, and varied subregion sizes. The baseline
epidemic with no vaccination was calibrated to the simulated
cholera incidence data for Matlab with no vaccination. Our
result that in populations like Matlab 50% vaccine coverage
should be sufﬁcient to control cholera remains valid for
variation in the season boost factor (Figure S16) and relative
infectiousness (Figure S17). However, we did see variation
with respect to subregion size. For larger subregions (.6k m
2
each), 50% vaccine coverage was sufﬁcient for control. But
for very small subregions (0.04 km
2 each), the average overall
vaccine effectiveness approaches 75% with a vaccination
coverage of 70% (Figure S18). This lower effectiveness implies
that random mass vaccination may not be effective in small
subregions, and vaccination would have to concentrate on the
small subregions where transmission is occurring. This result
could be applicable to epidemic cholera in small, dense
settings such as refugee camps where coverage would have to
be high to control transmission.
Discussion
The results of this modeling study indicate that 50%
coverage with OCV could control cholera transmission in
endemic areas such as Matlab, Bangladesh through a
combination of direct and indirect effects.. At this level of
coverage, the model predicts an 89% reduction in cholera
cases even among the unvaccinated, and a 93% reduction
overall in the entire population. These results would apply
only where cholera is endemic and population levels of
immunity are relatively high. According to our simulations,
areas where susceptibility is 2–2.5 as great as Matlab would
need to have vaccine coverage of at least 70% to achieve
cholera control. Since vaccine-induced protection with
current OCV begins to wane after about two years,
populations would have to be vaccinated biennially. This
could be done in advance of the cholera season for regions
that have clear seasonality. Alternatively, environmental
predictors of cholera outbreaks could be sampled in regions
where such a prediction capacity exists, and then vaccination
could take place in advance of expected outbreaks. In
environmental studies of cholera outbreak predictors in rural
Bangladesh, increases in cholera incidence can be predicted
several weeks in advance by water temperature, water depth,
rainfall, conductivity, and copepod counts [14]. Such pre-
dictors have been developed for Bangladesh and parts of
Latin America, but also need to be developed for other
regions with substantial risk, especially in Africa. Rapid mass
vaccination could take place after such predictors indicate
that outbreaks are likely. Further research needs to be carried
out on environmental predictors of cholera incidence to
make such an assessment reliable. For endemic cholera,
population-level immunity is relatively high, making control
possible with relatively low vaccine coverage levels. For
epidemic cholera, where population level immunity may not
be high, rapid vaccination could also be beneﬁcial, but further
study would be required to determine the higher coverage
levels necessary to obtain substantial indirect protection.
The results of our analysis are based on a mathematical
model closely calibrated to cholera incidence data from a
large-scale cholera vaccine trial in Matlab, Bangladesh. We
would hope that the model captures the dynamics of endemic
cholera sufﬁciently to allow us to evaluate the effectiveness of
cholera vaccination at different coverage levels in other
settings. However, a major limitation of this research is that
the results are only as good as the data the model is based on
and the veracity of the modeling assumptions. Veriﬁcation of
the results needs to take place through further community
Figure 4. Average Overall Vaccine Effectiveness When Varying Relative
Susceptibility
These comparisons are for relative susceptibility in populations ranging
from 1.5 to 2.5 times as susceptible as Matlab. The Matlab results are
shown when the multiplier is 1. For populations that are 2–2.5 times as
susceptible as Matlab, at least 70% vaccine coverage is needed to
achieve an overall effectiveness of at least 80%. The vaccine efficacies are
preset at VES ¼ 0.7 and VEI ¼ 0.5.
doi:10.1371/journal.pmed.0040336.g004
Table 2. Average Indirect, Total, and Overall Effectiveness of Vaccination, and Cases Prevented Per 1,000-Dose Regimens
Vaccination Coverage (%) Mean Effectiveness (%) (95% CI) Mean Cases Prevented per 1,000
Dose Regimens
a (95% CI) Indirect Total Overall
10 30 ( 39 to 83) 76 (47 to 95) 34 ( 30 to 84) 40 ( 34 to 97)
30 70 (31 to 93) 90 (76 to 98) 76 (44 to 95) 30 (17 to 36)
50 89 (72 to 98) 97 (91 to 99) 93 (82 to 99) 21 (19 to 23)
70 97 (91 to 99) 99 (97 to 100) 98 (95 to 100) 16 (15 to 17)
90 99 (98 to 100) 100 (99 to 100) 100 (99 to 100) 13 (12 to 14)
aRegimens comprised two doses of OCV.
doi:10.1371/journal.pmed.0040336.t002
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variety of geographic locations. A number of such vaccine
trials are currently being planned. The modeling methods
presented here can be used to help guide the design, analysis,
and interpretation of such trials. Based on the results of such
trials, such a model can be used to aid in designing successful
cholera vaccination strategies. A second limitation of the
model is that we have not explicitly modeled the level of
natural immunity in populations with endemic cholera, but
rather we alter the per-contact transmission probability to
reﬂect different levels of immunity. This means that we can
only approximate the effects of such immunity. More study is
needed in this area.
We have not explicitly addressed how to target vaccines
during a mass cholera vaccination campaign. In endemic
cholera regions, partial immunity tends to increase with
increasing age, as partially reﬂected in higher cholera
incidence rates among the young [6,10]. In addition, it could
take up to a month to vaccinate large populations. Although
we would recommend vaccinating all age groups 2 y and over,
with limited quantities of vaccine or time for administration,
we would recommend the targeted vaccination of children,
especially the very young.
The present analysis implies that mass immunization with
killed, whole-cell based oral cholera vaccines could possibly
confer a major protective impact against cholera in an
endemic setting, even with modest levels of vaccine coverage,
due to the combination of direct and indirect vaccine
protective effects. It might, however, be questioned whether
mass immunization with such vaccines is logistically feasible
and affordable. Feasibility of delivery of two-dose regimens of
B subunit–killed whole cell or whole cell-only oral cholera
vaccines has been demonstrated in a stable refugee setting
and a densely populated urban area in sub-Saharan Africa
[18,19], as well as in an urban setting in Asia [4]. Although the
cost of the B subunit–killed whole cell vaccine, which is
produced by an international producer, may currently
impede its use in developing country settings, we believe
that a low-cost vaccine could be made available in the near
future, pending regulatory issues. For example, the cost of
purchase and delivery of a two-dose regimen of a currently
available oral killed whole cell-only vaccine produced in
Vietnam was only US$0.89 in Vietnam [4]. There is currently
only one oral cholera vaccine, Dukoral, a B subunit–killed
whole cell vaccine, in production and internationally licensed
for people 2 y of age and older. This vaccine could be used in
mass vaccination campaigns such as that undertaken against
epidemic cholera in Mozambique in 2003–2004, with or
without targeting of young children. The success of the
vaccination campaign in Mozambique against a cholera
epidemic in an endemic region demonstrates that cholera
could be controlled with a relatively modest ﬁnancial
investment and an organized global surveillance and vacci-
nation program. However, the cholera situation in particular
regions should be carefully analyzed and modeled to
investigate the coverages and vaccination strategies that
would work best.
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southeast of the country’s capital, Dhaka at 23.388 north latitude and
90.728 east longitude.
(B) Close-up of Chandpur district, within which Matlab is contained.
(C) Rectangular grid mapped onto the Matlab region. The total area
of the grid was approximately 384 km
2. This area was divided into 64
rectangular subregions of approximately 6 km
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contained within 43 of these subregions, shown in yellow in the ﬁgure.
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Calibration runs were performed with 0% (A), 30% (B), 50% (C), and
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Found at doi:10.1371/journal.pmed.0040336.sg006 (82 KB PPT).
Figure S7. Average Cholera Incidence Rates for Different Vaccine
Coverage Levels
These simulations are for scenarios with vaccine coverage in the
entire population (2 y and older in age) ranging from 30% to 70%.
The solid line shows the average incidence among unvaccinated
people, the dashed line among vaccinated people.
Found at doi:10.1371/journal.pmed.0040336.sg007 (43 KB PPT).
Figure S8. Effect on Incidence When Varying the VES and Vaccine
Coverage
The solid lines show the average incidence among unvaccinated
people, the dashed lines among vaccinated people.
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Coverage
The solid lines show the average incidence among unvaccinated
people, the dashed lines among vaccinated people.
Found at doi:10.1371/journal.pmed.0040336.sg012 (48 KB PPT).
Figure S13. Effect on Average Indirect Vaccine Effectiveness When
Varying the VEI and Vaccine Coverage
Found at doi:10.1371/journal.pmed.0040336.sg013 (41 KB PPT).
Figure S14. Effect on Average Total Vaccine Effectiveness When
Varying the VEI and Vaccine Coverage
Found at doi:10.1371/journal.pmed.0040336.sg014 (41 KB PPT).
Figure S15. Effect on Average Overall Vaccine Effectiveness When
Varying the VEI and Vaccine Coverage
Found at doi:10.1371/journal.pmed.0040336.sg015 (42 KB PPT).
Figure S16. Effect on Average Overall Vaccine Effectiveness When
Varying the Seasonal Boost
Found at doi:10.1371/journal.pmed.0040336.sg016 (43 KB PPT).
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Controlling Endemic CholeraFigure S17. Effect on Average Overall Vaccine Effectiveness When
Varying the Relative Infectiousness of Symptomatic Infectives
Found at doi:10.1371/journal.pmed.0040336.sg017 (43 KB PPT).
Figure S18. Effect on Average Overall Vaccine Effectiveness When
Varying Subregion Sizes
Found at doi:10.1371/journal.pmed.0040336.sg018 (42 KB PPT).
Table S1. Model Parameters and Functions
Found at doi:10.1371/journal.pmed.0040336.st001 (33 KB DOC).
Text S1. Simulator Overview and Population Structure
Found at doi:10.1371/journal.pmed.0040336.sd001 (34 KB DOC).
Text S2. Infection Function
Found at doi:10.1371/journal.pmed.0040336.sd002 (45 KB DOC).
Text S3. Model Calibration and Sensitivity Analyses
Found at doi:10.1371/journal.pmed.0040336.sd003 (34 KB DOC).
Video S1. Animated Maps of Matlab Show the Spatial–Temporal
Distribution of Cholera Cases over the First 100 Days of Cholera
Epidemics when 0%, 10%, and 30% Vaccination Coverage Is
Implemented
Each animation is based on a single, representative run of the
simulator. For each coverage level, the map shows red dots, indicating
baris with at least one cholera case, and yellow dots, indicating baris
in which cases occurred but have recovered or died. Beneath each
animated map is the corresponding animated epidemic curve,
showing the number of cholera cases occurring each day.
Found at doi:10.1371/journal.pmed.0040336.sv001 (6.3 MB AVI).
Video S2. Animated Maps of Matlab Show the Spatial–Temporal
Distribution of Cholera Cases over the First 100 Days of Cholera
Epidemics when 50%, 70%, and 90% Vaccination Coverage Is
Implemented
Each animation is based on a single, representative run of the
simulator. For each coverage level, the map shows red dots, indicating
baris with at least one cholera case, and yellow dots, indicating baris
in which cases occurred but have recovered or died. Beneath each
animated map is the corresponding animated epidemic curve,
showing the number of cholera cases occurring each day.
Found at doi:10.1371/journal.pmed.0040336.sv002 (4.0 MB AVI).
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Background. Throughout history, there have been devastating out-
breaks of cholera—a gut infection characterized by diarrhea and severe
dehydration—around the world. These days, cholera is mainly confined
to developing countries where it disrupts social structures, impedes
economic development, and probably causes about 100,000 deaths a
year. People get cholera, which is caused by a bacterium called Vibrio
cholerae, by eating food or drinking water contaminated with feces
(stools) from an infected person. Most infected people have no or mild
symptoms but shed the bug in their feces for up to two weeks. Other
people develop severe diarrhea, producing stools that look like water
with flecks of rice in it. If untreated, patients with severe cholera can die
from dehydration within hours of developing symptoms. The standard
treatment for cholera is replacement of the fluids and salts lost through
diarrhea by drinking an oral rehydration solution or, in the worst cases,
by fluid replacement directly into a vein. Without this treatment, which is
not always available in the developing countries where cholera is
endemic (always present), one in every two people with severe
symptoms die.
Why Was This Study Done? The best way to control cholera is to ensure
that everyone has access to safe water and good sanitation, but this is
not possible in some poor countries, in refugee camps, or after natural
disasters such as floods. Oral cholera vaccines (preparations given by
mouth that stimulate the immune system to attack V. cholerae) are
available but they are not 100% effective and the protection they
provide wanes over time. Consequently, vaccination has not been
adopted as a control measure for endemic cholera. Recently, however,
researchers have suggested that oral cholera vaccines induce ‘‘herd
immunity.’’ With a disease that passes between people, when most of
the population is immune to it, it is unlikely that an infected person will
come into contact with a susceptible person and pass the disease on. In
effect, both vaccinated and unvaccinated people are protected from the
disease. If cholera vaccines do induce herd immunity, then mass
immunization might help to control endemic cholera. In this study, the
researchers have used a mathematical model to investigate this
possibility.
What Did the Researchers Do and Find? The researchers built a large-
scale model of cholera transmission using information about the
population of Matlab, Bangladesh (a region where cholera is endemic),
together with data on the biology of cholera and data from a large oral
vaccine trial done in Matlab in the 1980s. They used this model to predict
whether cholera would be controlled after vaccination of different
proportions of the population. They found that cholera transmission
would be controlled if half the population in the region was vaccinated.
This level of vaccine coverage reduced the number of cholera cases
among unvaccinated people by 89% and among the entire population
by 93%. With only one-third of the population vaccinated, the number of
cases of cholera still fell by three-fourths. The model also predicted that
in areas where there is less natural immunity to cholera (the people in
Matlab are constantly exposed to V. cholerae, so they have some
immunity to the bug even without vaccination), 70% of the population
would probably need to be vaccinated to control cholera.
What Do These Findings Mean? These findings suggest that, because
of herd immunity, vaccinating only half the population could control
cholera transmission in endemic regions where there is a high level of
natural immunity. Where there is less natural immunity, more of the
population would need to be immunized. Although mass immunization
of even 70% of a population should be achievable, for maximal
protection against V. cholerae, two doses of the oral cholera vaccine
need to be given a week apart followed by a booster every two years. In
developing countries this regimen might not always be logistically
feasible or affordable. Furthermore, because the accuracy of the model’s
predictions depends on the assumptions made to construct it and on the
data incorporated into it, these findings need to be checked in field trials
in other endemic areas. Nevertheless, these findings suggest that public-
health officials should consider including mass vaccination in their efforts
to control endemic cholera.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040336.
  The MedlinePlus encyclopedia contains a page on cholera (in English
and Spanish)
  Information is available from the World Health Organization on
cholera, including a fact sheet on the disease (in English, Spanish,
French, Russian, Arabic, and Chinese)
  The US Centers for Disease Control and Prevention provide informa-
tion on cholera (in English, Spanish and Portuguese).
  The UK National Health service provides simple information on
vaccines and immunization, which includes an animation that explains
herd immunity
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